Pfizer's Obesity Drug Shows 16% Weight Loss In Phase 2b Study

Pfizer Inc. (NYSE:PFE) shares are trading lower by almost 1% on Monday as the company shared data from Phase 2b studies of berobenatide, an investigational GLP-1 receptor agonist for weight management.

Pfizer Berobenatide Update

On Saturday, the company reported that the Phase 2b studies for berobenatide demonstrated a non-placebo-adjusted weight loss of 15.9% in participants.

The pivotal Phase 3 study is currently open for enrollment, which may further bolster Pfizer’s position in the obesity treatment market.

Pfizer plans to advance 10 Phase 3 studies for berobenatide in 2026 for chronic weight management and obesity-related comorbidities, including knee osteoarthritis and obstructive sleep apnea, as part of a broader program of 20+ obesity trials.

The first clinical experience with the top weekly dose for berobenatide is were presented for the first time.

Results from a 32-week exploratory extension (Part B) of the Phase 2b VESPER-1 study showed a non-placebo-adjusted weight loss of 15.9% with no plateau observed at 32 weeks on berobenatide (Week 60 of the overall study), in participants who escalated from placebo to 2.4 mg weekly berobenatide.

Phase 3 Program Expands

The VESPER-6 pivotal Phase 3 study investigating monthly maintenance dosing for berobenatide in obese adults is open for enrollment, as well as the SOLIS-1 Phase 2b study investigating weekly and monthly maintenance dosing of an ultra-long-acting amylin analog (PF’3945) as a monotherapy and in combination with berobenatide.

FDA Expands HYMPAVZI Indication

On Monday, the U.S. Food and Drug Administration (FDA) approved an expanded indication for Pfizer’s HYMPAVZI (marstacimab-hncq) to include hemophilia A or B patients 12 years and older with inhibitors and pediatric patients (ages 6 to 11 years) with or without inhibitors.

HYMPAVZI is the first subcutaneous non-factor therapy available for pediatric patients with hemophilia B aged 6 to 11 years.

PFE Stock Price Activity: Pfizer shares were down 1.3% at $25.70 at the time of publication on Monday, according to Benzinga Pro data.

Photo: Molly Woodward / Shutterstock